Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Foghorn Therapeutics ( (FHTX) ) is now available.
In September 2025, Foghorn Therapeutics presented its strategic advancements in precision therapeutics, highlighting its collaboration with Lilly on the FHD-909 program. The company is pioneering selective inhibitors and degraders for cancer treatment, with significant potential in addressing unmet needs in oncology. This collaboration, initiated with a landmark agreement in December 2021, underscores Foghorn’s commitment to innovation and positions it strongly within the industry, offering multi-billion dollar opportunities.
The most recent analyst rating on (FHTX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.
Foghorn Therapeutics’ overall stock score is primarily impacted by its challenging financial performance, characterized by persistent losses and high leverage. Technical analysis provides some neutral signals, while valuation remains unattractive due to negative earnings. Positive corporate developments are noted but do not significantly alter the financial outlook.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. operates in the biotechnology industry, focusing on precision therapeutics targeting chromatin biology. The company aims to develop first-in-class therapies for oncology, leveraging its Gene Traffic Control Platform® to address challenging targets implicated in various cancers.
Average Trading Volume: 118,623
Technical Sentiment Signal: Strong Sell
Current Market Cap: $286M
For an in-depth examination of FHTX stock, go to TipRanks’ Overview page.